Godsey & Gibb Associates Alnylam Pharmaceuticals, Inc. Transaction History
Godsey & Gibb Associates
- $1.11 Billion
- Q3 2025
A detailed history of Godsey & Gibb Associates transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Godsey & Gibb Associates holds 28 shares of ALNY stock, worth $12,395. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28Holding current value
$12,395% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
830Shares Held
118MCall Options Held
584KPut Options Held
648K-
Capital World Investors Los Angeles, CA16.8MShares$7.44 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.01 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.23 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.18 Billion0.49% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.01 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $54.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...